High risk kidney transplant rejection treatment: cost savings from thymoglobulin

Transplant Proc. 1999 Feb-Mar;31(1-2):269-71. doi: 10.1016/s0041-1345(98)01530-9.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antilymphocyte Serum / economics
  • Antilymphocyte Serum / therapeutic use*
  • Black People
  • Black or African American
  • Costs and Cost Analysis
  • Demography
  • Diabetic Nephropathies / surgery
  • Double-Blind Method
  • Graft Rejection / drug therapy*
  • Humans
  • Immunosuppressive Agents / economics
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Failure, Chronic / surgery
  • Kidney Transplantation / immunology*
  • Missouri
  • Reoperation
  • Risk Factors
  • Tissue Donors

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents